Hyperfine, Inc. provides imaging, monitoring, and magnetic resonance imaging products. It offers Swoop Portable MR imaging system to address an unmet need in point-of-care medical imaging through a combination of hardware and software services. The company was incorporated in 2014 and is based in Guilford, Connecticut.
IPO Year: 2021
Exchange: NASDAQ
Website: https://hyperfine.io
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/11/2022 | $8.00 → $2.40 | Overweight → Equal Weight | Wells Fargo |
| 5/31/2022 | $7.00 | Outperform | Evercore ISI |
| 4/14/2022 | $8.00 | Overweight | Wells Fargo |
Fastest customizable press release news feed in the world
GUILFORD, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced second quarter 2025 financial results and provided a business update. "In the second quarter, we executed across our key growth drivers. We received FDA clearances for our latest software, Optive AITM, and for the next generation Swoop® system powered by Optive AITM software, which represent a key inflection point in our technology. We also completed our pilot neurology office program. We believe these criti
NEURO PMR study evaluates the clinical utility and patient experience of AI-powered portable MRI in an outpatient setting Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system— today announced the successful enrollment of 100 patients in its NEURO PMR (Neurological Evaluation in the Office with Portable MRI) study just 16 weeks after the study initiation, announced on April 15, 2025. This milestone reflects strong clinician enthusiasm for accessible, point-of-care brain imaging and supports Hyperfine's market expansion into outpatient neurology o
The real-world study will assess the clinical and operational impact of portable MRI across diverse patient types in ED settings. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance imaging (MRI) system for the brain—the Swoop® system—today announced the enrollment of the first patients in the PRIME (Portable Rapid Imaging for Medical Emergencies) study. This study aims to evaluate the potential of AI-powered portable MRI technology to transform triage in the emergency department (ED) setting. The PRIME study at Yale School of Medicine builds on the ACTION PMR study
Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that it will report financial results for the second quarter 2025 on Wednesday, August 13, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. About the Swoo
Interim results from the CARE PMR study support the use of ultra-low-field MRI as a triage tool for monitoring patients on amyloid-targeting therapies. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—announced promising early results from the CARE PMR (Capturing ARIA Risk Equitably with Portable MR) study presented at the 2025 Alzheimer's Association International Conference in Toronto, Canada. Researchers from the Benzinger Lab at Washington University School of Medicine in St. Louis reported interim results from 31 Alzheimer's patients
New dementia study actively enrolling and new data to be presented at the 2025 Alzheimer's Association International Conference. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced two significant advancements highlighting the potential of its innovative MRI technology to expand dementia screening, enhance monitoring, and improve care. Globally, over 57 million people live with dementia, with Alzheimer's disease accounting for 60–80% of cases (Centers for Disease Control, World Health Organization). Limited access to conventio
Optive AI™ software has now been installed in an initial set of hospitals and neurology offices across the U.S., marking the beginning of expanded access to transformative, AI-powered image quality from portable, ultra-low-field MRI systems. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced the commercial launch of the Optive AI™ software for existing Swoop® system customers. Optive AI™ software, which also powers the transformative image quality of the next-generation Swoop® system, is now commercially available to customers
Following the recent clearance of the new Swoop® System, two leading hospitals in the United States have purchased the first commercial units, marking the launch of next-generation portable MR brain imaging. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—announced today the first commercial sales of the next-generation Swoop® system powered by proprietary Optive AI™ software. Both of these pioneering hospitals plan to utilize the technology in intensive care units and emergency department settings. The initial sales of the next-generatio
Rafael O'Halloran, PhD, and Rob Fasciano, PhD, bring depth and breadth of experience in imaging and Medtech. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—announced the appointments of Rob Fasciano, PhD, as Chief Regulatory and Quality Officer, and Rafael O'Halloran, PhD, as Vice President of Technology. These leadership additions were instrumental in the development of the recently FDA-cleared Optive AI™ software and the new, next-generation Swoop® scanner. Their work will greatly aid the rollout of this new technology globally and the d
This major Swoop® system scanner redesign and Optive AI™ software elevate the AI-powered portable MRI experience for clinicians and their patients across multiple sites of care. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—announced today FDA clearance of its most significant technological advancement to date. The clearance includes an entirely new portable MRI scanner powered by the proprietary Optive AI™ software. This new system delivers the highest level of image quality, functionality, and usability to date, unlocking a new brain im
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Wells Fargo downgraded Hyperfine from Overweight to Equal Weight and set a new price target of $2.40 from $8.00 previously
Evercore ISI initiated coverage of Hyperfine with a rating of Outperform and set a new price target of $7.00
Wells Fargo initiated coverage of Hyperfine with a rating of Overweight and set a new price target of $8.00
10-Q - Hyperfine, Inc. (0001833769) (Filer)
8-K - Hyperfine, Inc. (0001833769) (Filer)
8-K - Hyperfine, Inc. (0001833769) (Filer)
8-K - Hyperfine, Inc. (0001833769) (Filer)
8-K - Hyperfine, Inc. (0001833769) (Filer)
424B5 - Hyperfine, Inc. (0001833769) (Filer)
10-Q - Hyperfine, Inc. (0001833769) (Filer)
8-K - Hyperfine, Inc. (0001833769) (Filer)
8-K - Hyperfine, Inc. (0001833769) (Filer)
DEFA14A - Hyperfine, Inc. (0001833769) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Hyperfine, Inc. (0001833769) (Issuer)
4 - Hyperfine, Inc. (0001833769) (Issuer)
4 - Hyperfine, Inc. (0001833769) (Issuer)
4 - Hyperfine, Inc. (0001833769) (Issuer)
4 - Hyperfine, Inc. (0001833769) (Issuer)
4 - Hyperfine, Inc. (0001833769) (Issuer)
4 - Hyperfine, Inc. (0001833769) (Issuer)
4 - Hyperfine, Inc. (0001833769) (Issuer)
4/A - Hyperfine, Inc. (0001833769) (Issuer)
4 - Hyperfine, Inc. (0001833769) (Issuer)
Live finance-specific insights
GUILFORD, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced second quarter 2025 financial results and provided a business update. "In the second quarter, we executed across our key growth drivers. We received FDA clearances for our latest software, Optive AITM, and for the next generation Swoop® system powered by Optive AITM software, which represent a key inflection point in our technology. We also completed our pilot neurology office program. We believe these criti
Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that it will report financial results for the second quarter 2025 on Wednesday, August 13, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. About the Swoo
Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the first quarter 2025 on Tuesday, May 13, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. About the Swo
Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the fourth quarter and full year 2024 on Monday, March 17, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call
GUILFORD, Connecticut, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced third quarter 2024 financial results and provided a business update. "The Hyperfine team delivered yet another strong quarter of financial performance across revenue growth, gross margin expansion, and disciplined cash management while executing against several important priorities in our plans to expand into new sites of care and internationally," said Maria Sainz, Chief Executive Officer and President of Hy
Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the third quarter 2024 on Tuesday, November 12, 2024. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. About th
─ Reports $3.6M in Q2 2024 Revenue; 50% Gross Margin─ Raises FY 2024 Revenue Guidance to $13-16M GUILFORD, Conn., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced second quarter 2024 financial results and provided a business update. "I am proud of the Hyperfine team, achieving record revenue and delivering meaningful progress across innovation and clinical initiatives in the quarter," said Maria Sainz, Chief Executive Officer and President of Hyperfine, Inc. "The opportunities ahead
Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the second quarter 2024 on Thursday, August 8, 2024. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the presentation will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. Abou
GUILFORD, Conn., May 13, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced first quarter 2024 financial results and provided a business update. "We have kicked off 2024 strong. I am pleased with our commercial progress shown by sales across US and international accounts, as well as the important milestones we hit in Q1 by commencing CARE PMR study enrollment in Alzheimer's and launching our 8th generation AI-powered software," said Maria Sainz, Chief Executive Officer and President of Hyperfin
Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the first quarter 2024 on Monday, May 13, 2024. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the presentation will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. About the
This live feed shows all institutional transactions in real time.
SC 13G - Hyperfine, Inc. (0001833769) (Subject)
SC 13G/A - Hyperfine, Inc. (0001833769) (Subject)
SC 13G/A - Hyperfine, Inc. (0001833769) (Subject)
SC 13D/A - Hyperfine, Inc. (0001833769) (Subject)
SC 13G - Hyperfine, Inc. (0001833769) (Subject)
SC 13G/A - Hyperfine, Inc. (0001833769) (Subject)
SC 13D - Hyperfine, Inc. (0001833769) (Subject)
Live Leadership Updates
Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T
Two new executive roles position Hyperfine to drive the adoption of the Swoop® system in hospital settings and expand into the office setting, laying the foundation for significant growth in 2025 and beyond. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced the appointment of Chi Nguyen as Vice President of Office Strategy and Partnerships and Rafael Donnay as Vice President of Hospital Strategy and Health Economics to provide leadership in key growth areas. These strategic leadership appointments bolster t
Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and underserved MRI market Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced it has entered into a distribution agreement with Radiosurgery Global, Ltd. to develop the market in India. The distribution agreement also includes the countries of Malaysia, Indonesia, and Singapore through future expansion, offering Hyperfine, Inc. a significantly increased presence in Asia. The clinical value of the Swoop®
- Distributors appointed in France, the United Kingdom, and Italy - Industry veteran Enrico Barini joins as International Business Development Director Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced it has entered into agreements with three experienced and accomplished distributors to support commercial expansion plans of the Swoop® system into European markets with an initial focus on France, the United Kingdom, and Italy. In 2023, Hyperfine, Inc. obtained CE certification under the EU MDR and UKCA certificati
BUFFALO, N.Y., Nov. 29, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII) ("22nd Century" or the "Company"), a biotechnology company focused on utilizing advanced plant technologies to improve health and wellness, today announced the appointment of Lawrence (Larry) Firestone as the Company's Chairman and Chief Executive Officer. Nora Sullivan, former Chair of the Board, commented, "Larry is a seasoned executive known for his 'hands-on' leadership style emphasizing teamwork, business alignment, continuous improvement, cost control and process optimization. His track record of success with fast growing public companies will serve 22nd Century well as it continues to execu
In addition to the study, the company appoints a world-class stroke advisory board as part of its acute ischemic stroke initiatives Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable magnetic resonance brain imaging system, has announced the commencement of an international, multi-site observational study, ACTION PMR (ACuTe Ischemic strOke detectioN with Portable MR). To support its acute stroke care initiatives, Hyperfine Inc. has formed an advisory board of world-renowned stroke experts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2
SAN JOSE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced today the appointment of Tamara Elias, M.D., Senior Vice President at Nuance, and Scott Huennekens, executive chairperson at Hyperfine, Wondr Medical, Acutus Medical and Envista Holdings Corporation, to the BrightInsight Advisory Council. Dr. Elias and Huennekens bring deep and complimentary experience to this group of industry experts, who work with BrightInsight leadership to advance the company's vision to transform patient outcomes globally through the power of digital technology. Dr. Elias and Huennek
GUILFORD, Conn., June 14, 2022 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), creator of the Swoop® Portable MR Imaging System™, the world's first US FDA-cleared portable magnetic resonance imaging (MRI) device, announced today that it has completed registration and notification of the device in Australia and New Zealand. With this activity, the Swoop system is now available for purchase in Australia and New Zealand and includes the US FDA-cleared advanced reconstruction software using deep learning. Multiple pilot research units have been ordered across key Australian cities bolstering Hyperfine's entry into these two markets and laying the foundation for commercial efforts. Hyperfin
Former Google Health Executive to Expand Cardiovascular Strategy for Ocular Health Technology Company Tesseract Health, a health technology company developing a portable, non-invasive platform to detect health conditions through the eyes, proudly announces the appointment of Michael McConnell, MD, MSEE, as Tesseract's Head of Cardiovascular and Digital Health. This key role completes Tesseract's leadership team and coincides with a series of critical, strategic hires under the helm of CEO Vicky Demas, PhD. Dr. McConnell was brought on to leverage Tesseract's technology to guide the expansion of its cardiovascular strategy. In this role, he is poised to lead and champion the design, planni
GUILFORD, Conn., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Hyperfine Inc. (NASDAQ:HYPR), creator of Swoop®, the first FDA-cleared portable magnetic resonance imaging (MRI) system™, today announced the appointment of Dr. Chip Truwit as senior medical director. For more than 30 years, Truwit has committed his talents to clinical practice in public sector healthcare and neuroradiology education. "We feel privileged to welcome Dr. Truwit to the Hyperfine team," Khan Siddiqui, M.D., Hyperfine's chief medical officer and chief strategy officer, said. "His remarkable experience in neuroradiology and his work with underserved communities will make considerable contributions to the Hyperfine mission of in